Back to search

Article

A Phase I Study of MLN4924 and Belinostat in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

2024-10-14

Abstract excerpt

<title>Abstract</title> <p>Purpose: Relapsed and/or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome continue to have a poor prognosis with limited treatment options despite advancements in rational combination and targeted therapies. Belinostat (an HDAC inhibitor) and Pevonedistat (a NEDD8 inhibitor) have each been independently studied in hematologic malignancies and have tolerable safe...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
fe65f4e1-0c55-5864-8600-e554db93a9ce
DOI
10.21203/rs.3.rs-4889008/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
A Phase I Study of MLN4924 and Belinostat in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeDOI 10.21203/rs.3.rs-4889008/v1
Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.Semantic proximity
Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AMLSemantic proximity
Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate‐1 risk myelodysplastic syndromeSemantic proximity
Vorinostat Induces Apoptosis and Differentiation in Myeloid Malignancies: Genetic and Molecular MechanismsSemantic proximity
Vorinostat in acute myeloid leukemia and myelodysplastic syndromesSemantic proximity
Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome.Semantic proximity
Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes.Semantic proximity
Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia modelsSemantic proximity
Outcomes of Patients With IDH1-Mutated Myeloid Neoplasms Treated With Olutasidenib.Semantic proximity
FDA Approval Summary: Ivosidenib for Treatment of Adult Patients with Relapsed/Refractory Myelodysplastic Syndrome with an IDH1 Mutation.Semantic proximity
Lenalidomide in patients with red blood cell transfusion-dependent myelodysplastic syndrome and del(5q): a single-centre "real-world" experience.Semantic proximity
A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.Semantic proximity
Select a neighboring publication to make it the new centre.